RT Journal Article
SR Electronic
T1 COVID-19 vaccine breakthrough infections among fully vaccinated Health Care Workers in Lagos, Nigeria
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.22.22276765
DO 10.1101/2022.06.22.22276765
A1 Oladele, David A.
A1 Salako, Abideen
A1 Ayorinde, James
A1 Onwuamah, Chika
A1 Usman, Olagoke
A1 Abubakar, Rufai
A1 Liboro, Gideon
A1 Odubela, Oluwatosin
A1 Mogaji, Sunday
A1 Ige, Fehintola
A1 Ohihoin, Gregory
A1 Ezechi, Oliver
A1 Audu, Rosemary
A1 Adegbola, Richard A.
A1 Dada, Adedamola
A1 Salako, Tunde
YR 2022
UL http://medrxiv.org/content/early/2022/06/22/2022.06.22.22276765.abstract
AB Background Access to vaccines has contributed to the control of COVID-19. However, evaluation of the effectiveness of the vaccines in a setting where the vaccines were not originally tested is critically important. This study evaluates the clinical and laboratory characteristics of COVID-19 vaccine breakthrough infections among healthcare workers (HCWs).Methods A multicentre prospective study among HCWs who had two doses of the Oxford/AstraZeneca ChAdOx1-S [recombinant] (AZD1222) vaccine were followed up 24 weeks. Nasopharyngeal and oropharyngeal specimens were tested using RT-PCR for SARS-CoV-2 and positive samples were subjected to whole genome sequencing for variant assignment.Result A total of 369 HCWs were enrolled; of which 24 (6.5%) had breakthrough infections. There was equal sex distribution among the breakthrough cases. The majority were aged between 30 to 39years (37.5%), and had mild symptoms of cough, fever, headache, and nausea/vomiting (58%), with no hospitalization. Among the 24 breakthrough cases whose whole genomes were successfully sequenced, three were confirmed to be Delta B.1.617.2 variant during the 3rd wave and an additional three were confirmed as omicron B.1.1.529 variant during the 4th wave.Conclusion We reported vaccine breakthrough cases among fully vaccinated HCWs with the majority presenting with mild illness. Both delta and omicron variants were identified during the different epidemiologic spectrums of SARS-CoV-2. Therefore, there is a need to scale up vaccination for all front-line health workers and high-risk populations in developing countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Nigerian Institute of Medical research Institutional Review Board (email: nimr_irb{at}yahoo.com nimr-irb{at}nimr.gov.ng)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request through the IRB of the Nigerian Institute of Medical Research(email: nimr_irb{at}yahoo.com nimr-irb{at}nimr.gov.ng)